Ajanta Pharmaceuticals Q2 Results Live: Profit Rises by 10.84% YoY

Ajanta Pharmaceuticals Q2 Results Live : Ajanta Pharmaceuticals declared their Q2 results on 28 Oct, 2024, reporting a topline increase of 15.38% year-over-year and a profit increase of 10.84% YoY. However, when compared to the previous quarter, the revenue grew by only 3.64%, while the profit saw a significant decrease of 11.92%.

The company's Selling, General & Administrative expenses saw a decline of 8.04% quarter-over-quarter, although they increased by 17.41% year-over-year, indicating some cost control measures are being implemented.

Operating income also showed positive growth, up by 2.04% q-o-q and 17.7% YoY, highlighting the company's ability to maintain operational efficiency despite fluctuating expenses.

Earnings per Share (EPS) for Q2 stood at ₹17.26, reflecting an increase of 11.35% compared to the same quarter last year, which is a positive indicator for investors.

In terms of stock performance, Ajanta Pharmaceuticals has delivered a -6.93% return in the last week, but a robust 32.09% return over the last six months and a remarkable 40.26% year-to-date return.

The company's current market capitalization is ₹36,506.81 crore, with a 52-week high of ₹3,485 and a low of ₹1,730.90, illustrating significant volatility in its stock price.

As of 29 Oct, 2024, analysts' ratings reflect a mixed sentiment: out of 9 analysts covering the company, 2 have given a Strong Sell rating, 1 has a Hold rating, 4 have a Buy rating, and 2 have issued Strong Buy ratings.

The consensus recommendation as of 29 Oct, 2024, is to Buy, indicating a generally optimistic outlook for Ajanta Pharmaceuticals despite recent market fluctuations.